Powered by
Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
Mar 8, 2017 - Marketwire (Canada)

Data to be presented at Corbus Pharmaceuticals' upcoming R&D day on March 13th

NORWOOD, MA--(Marketwired - March 08, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox